Previous 10 | Next 10 |
U.S.-listed shares of small-cap pharmatech company Exscientia ( NASDAQ: EXAI ) fell 14.1% to $9.87 in Thursday morning trading after the company reported Q2 results. EXAI after hours on Wednesday posted Q2 non-GAAP EPS of -£0.29 which missed estimates by &...
The following slide deck was published by Exscientia plc in conjunction with their 2022 Q2 earnings call. For further details see: Exscientia plc 2022 Q2 - Results - Earnings Call Presentation
Exscientia press release ( NASDAQ: EXAI ): Q2 Non-GAAP EPS of -£0.29 misses by £0.11 . Revenue of £8.7M (+2075.0% Y/Y). For further details see: Exscientia Non-GAAP EPS of -£0.29 misses by £0.11, revenue of £8.7M
Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005681/en/ Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for ...
Today, we take our first look at Exscientia, a unique developmental concern using artificial intelligence or AI to help identify promising drug compounds. Its platform has drawn numerous collaboration deals from the likes of Sanofi and Bristol-Myers Squibb. An investment analysis ...
Company to host conference call and webcast on August 18, 2022 at 1:30 p.m. BST / 8:30 a.m. ET Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will...
July was the highest revenue generating month of 2022. The US hard to borrow equity market pushes revenues higher. Fixed income continues to see strong demand. Corporate bonds are in for an impressive 2022. Global securities finance revenues totalled $1.215 bln, ...
This year, two major catalysts for SoftBank are the potential sale of the Fortress Investments subsidiary and the Arm IPO. This complicated company has faced underperformance over the past few years, especially after the 2020 speculation boom. However, if valuation reaches a certa...
Persistent inflation will give rise to transformational investment across industries, according to Morgan Stanley. "While cyclical forces tend to deter investment in an uncertain macro environment, we believe structural changes in demographics, energy policy and security, and an agi...
AlphaFold is a leading open-source AI program that aids researchers in visualizing protein structures. Applications are diverse and reduce research time across the healthcare industry and academia. The program certainly is a gift to our future health, but the open source nature an...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...